Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Interleukin-2 Treatment in Moderate to Severe Chronic Spontaneous Urticaria With Poor Control by Antihistamines: a Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial

NCT06924762 is registered in ClinicalTrials.gov with Second Xiangya Hospital of Central South University as lead sponsor.

NCT NCT06924762
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06924762 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Interleukin-2 Treatment in Moderate to Severe Chronic Spontaneous Urticaria With Poor Control by Antihistamines: a Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial
Lead sponsor
Second Xiangya Hospital of Central South University
Phase
Phase 2/3
Overall status
Recruiting
Start date
March 19, 2025
Completion date
May 31, 2026
Enrollment
124 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic spontaneous uriticaria